Mesothelioma Life Expectancy: Survival Rates, Prognosis Factors, and Treatment Outlook
A mesothelioma diagnosis can be devastating for families who are suddenly facing concerns about their loved one’s health and uncertainty about their future. While mesothelioma is a severe and aggressive disease, learning more about its effects, stages, treatment options, and life expectancy can help you access the care and support you need to fight the disease and improve your quality of life.
This guide discusses mesothelioma life expectancy, survival rates, and the factors that can impact your prognosis, helping you navigate your treatment and what to expect.
NAVIGATE THIS PAGE
Understanding Mesothelioma Survival Rates and Life Expectancy
Mesothelioma Survival Rates by Type and Location
Critical Factors Affecting Mesothelioma Survival and Prognosis
Demographic Patterns in Mesothelioma Diagnosis and Survival
What Patients Can Do to Optimize Survival and Quality of Life
Understanding Your Personal Mesothelioma Prognosis
Conclusion: Taking Action to Improve Your Mesothelioma Outlook
Understanding Mesothelioma Survival Rates and Life Expectancy
Mesothelioma is a rare and aggressive cancer with a single confirmed cause—asbestos exposure. Patients and families affected by this deadly disease can better plan for dealing with a diagnosis by understanding the life expectancy and survival statistics. According to a review of the National Mesothelioma Virtual Bank, the average life expectancy for patients with pleural mesothelioma ranges from 12 to 21 months, although outcomes vary significantly based on numerous factors.
Data from the Surveillance, Epidemiology, and End Results Program, or SEER, and the National Cancer Institute show that the one-year survival rate for mesothelioma is 44.7%, while the five-year survival rate is 11.5%.
Life expectancy differs from survival rate. Life expectancy refers to the length of time a patient can expect to live, while survival rate is the percentage of patients who remain alive for a specific period after diagnosis. Both metrics are essential for understanding prognosis and treatment options.
What Do Mesothelioma Survival Statistics Really Mean?
Mesothelioma survival statistics are based on large patient populations and represent average outcomes. However, individual outcomes vary significantly. Some patients live much longer than average statistics suggest, while others may have shorter survival times. Finding the disease early, getting aggressive treatment, and working closely with a qualified medical team can greatly improve your chances.
Mesothelioma Survival Rates by Type and Location
The specific type and location of the disease play a critical role in shaping both your personalized treatment plan and your path forward. Because tumors in varying parts of the body affect specific organs, each type responds differently to treatment. Your care team can tailor therapies to the specific behavior of your cells and target the disease more effectively to support your overall well-being.
While every patient’s experience is unique and they may respond to treatment differently, listed below are the average survival rates for each type of mesothelioma:
Pleural
Lung lining (most common)
American Cancer Society
15%
17 months with treatment
Pleural
Lung lining (most common)
The data used in this manuscript analysis was contributed by collaborators at New York University, University of Pennsylvania, University of Maryland, School of Medicine, and Roswell Park Cancer Institute
15%
14 months
Peritoneal
Abdominal lining
Moffitt Cancer Center
9%
Not commonly reported
Peritoneal
Abdominal lining
The data used in this manuscript analysis was contributed by collaborators at New York University, University of Pennsylvania, University of Maryland, School of Medicine, and Roswell Park Cancer Institute
Not commonly reported
31 months
Peritoneal
Heart lining
Medical Journal: Seminars in Thoracic and Cardiovascular Surgery
Not commonly reported
2 months
Testicular
Testicle lining
Medical Journal: Cureus
58%
23 months
Pleural Mesothelioma: The Most Common Type
Pleural mesothelioma affects the lung lining and accounts for approximately 80% of all mesothelioma cases. This type of mesothelioma has a very challenging prognosis, with a 5-year survival rate of just 15%. However, patients who undergo multimodal therapy may live longer. Speak with your doctor to see what treatments and therapies are available to you.
Peritoneal Mesothelioma: Better Survival Outcomes
Peritoneal mesothelioma affects the abdominal lining. It comprises about 20% of cases, but patients with this type have significantly better survival prospects. The 5-year survival rate is 65%—more than four times that of pleural mesothelioma.
Key Finding
Peritoneal mesothelioma patients who receive aggressive, multimodal treatment—a combination of surgery, chemotherapy, and radiation—can have dramatically improved survival rates compared to those undergoing a singular treatment.
Critical Factors Affecting Mesothelioma Survival and Prognosis
The most critical factors affecting mesothelioma survival and prognosis are the stage of the cancer at diagnosis, the cell type, and the location of the primary tumor. Because mesothelioma is highly complex and involves many factors, survival statistics provide only broad guidelines rather than exact timelines.
Understanding these diverse factors empowers clinicians to develop individualized, life-extending treatment plans. Speak with your medical team for guidance on your prognosis and what you can expect.
Stage at Diagnosis
The stage of the cancer at diagnosis is one of the strongest predictors of survival. According to the American Cancer Society, mesothelioma is categorized into four stages based on how much the cancer cells have spread, where they are located, and several other factors.
However, the SEER database groups cancers as localized, regional, or distant. Localized cancer is found only in the initial organ or area and has not spread, while regional cancer has spread to nearby tissues, lymph nodes, or other parts of the body. Distant refers to cancer that has metastasized or spread to further parts of the body, separate organs, or bodily systems that are not near the original location of the cancer.
Based on the latest SEER numbers, the five-year survival rates for mesothelioma at different stages are:
- Localized: 21.7% survival rate
- Regional: 14.3% survival rate
- Distant: 8.8% survival rate
Generally, early detection of cancer can improve a patient’s prognosis. Patients who receive an early diagnosis of mesothelioma may have more treatment options that can impact their outcome. Consult a qualified doctor to learn more about available treatments after a diagnosis.
Cell Type
When pathologists look at a tumor sample under a microscope, they classify mesothelioma into three main cell types. The shape and behavior of these cells heavily influence how quickly the cancer grows and how it responds to medical care.
Epithelioid mesothelioma is the most common type of this cancer cell and typically has the best prognosis. Sarcomatoid mesothelioma has the lowest survival rate. Meanwhile, biphasic mesothelioma involves both epithelial and sarcomatoid cells.
Among patients who received treatment for mesothelioma, the following are the median survival rates for each cell type:
Epithelioid
Best Prognosis
14 months; 19 months with surgery
Biphasic
Intermediate Prognosis
10 months; 12 months with surgery
Sarcomatoid
Poorest Prognosis
4 months; no change with surgery
Based on THIS SOURCE (Medical Journal: Journal of Surgical Research via PubMed)
Age and Gender
Age can significantly impact survival outcomes for mesothelioma. Patients diagnosed before age 40 have higher survival rates than older patients.
Gender also plays a role in mesothelioma survival rates. Past numbers showed that women had a survival rate that was three times higher than that of men. However, according to the latest SEER data, that gap may have narrowed slightly, with women having about twice the survival rate as men. The following are the five-year survival rates based on gender from 2016 through 2022:
- Women with mesothelioma: Five-year survival rate of 23.4%
- Men with mesothelioma: Five-year survival rate of 12.2%
Women’s improved outcomes may be attributed to earlier diagnosis at younger ages and a higher likelihood of the cancer having the epithelioid cell type. However, every patient is different. Talk to your doctor about how your age or gender may impact your prognosis.
Overall Health and Comorbidities
A patient’s overall general health and existing comorbidities can affect mesothelioma treatment eligibility and survival rates. Aggressive therapies, such as radical surgeries and intensive chemotherapy regimens, require physical and mental resilience. Healthier patients may be better able to tolerate these demanding, multimodal interventions.
Conversely, preexisting cardiovascular or pulmonary diseases often restrict treatment options to merely palliative care. It’s best to discuss your current health and treatment options with your medical team.
Treatment Received
The types of treatment available to a patient with mesothelioma can impact life expectancy and improve symptoms. Many studies have shown that a multimodal approach that includes surgery, chemotherapy, immunotherapy, and radiation or other combinations of treatment modalities is most effective for mesothelioma patients.
Along with standard treatment approaches and traditional therapies, some patients choose to incorporate other approaches into their care plan, including a focus on diet and activity levels. Interventions that improve physical activity and muscle mass may benefit mesothelioma patients and improve their outcomes.
Demographic Patterns in Mesothelioma Diagnosis and Survival
Mesothelioma statistics shared by the CDC show certain demographic patterns in diagnosis, prevalence, and survival rates in patients. Based on an analysis of new mesothelioma cases in the United States, 47,973 males were reportedly diagnosed with the disease between 2003 and 2022, while 15,647 females were diagnosed over the same timeframe.
By age, mesothelioma is mostly diagnosed in people over the age of 75, with the highest incident rates shifting between the age groups of 75 through 84 and 85 and older from 2003 to 2022. Based on mesothelioma cases reported in the United States in 2022, here is the age distribution of diagnoses:
80 years and older
7.3
75-84
5.8
65-74
2.1
55-64
0.7
45-54
0.3
Younger than 45
0.1
BASED ON THIS SOURCE (CDC) – Rate of New Mesothelioma Cases by Age (2022 Data)
Numbers from the SEER database show the prevalence of mesothelioma by age group on January 1, 2023, as follows:
Ages 75+
2,639
Ages 65-74
1,689
Ages 50-64
1,545
Ages < 50
677
What Patients Can Do to Optimize Survival and Quality of Life
While mesothelioma is a serious diagnosis, patients can take several evidence-based actions to improve their prognosis and quality of life. Active participation in your care plan can directly influence both treatment outcomes and how you feel.
Early Diagnosis and Specialized Treatment
While there is no standard testing for mesothelioma, symptoms of the disease generally include the following:
- Difficulties breathing
- Coughing
- Pain under the rib cage
- Pain, swelling, or lumps in the abdomen
- Weight loss with no known cause
- Feeling overly fatigued
If you experience any of the above, consult your doctor immediately. Prompt testing and imaging provide the best chance of an early diagnosis.
Because mesothelioma is rare and complex, general oncologists see very few cases. A cancer specialist experienced with mesothelioma cases may be able to help you access the best treatments and advanced therapies.
Pursue Aggressive Multimodal Treatment
Studies have shown that the most successful treatment approaches for mesothelioma combine multiple therapies, such as surgery, chemotherapy, immunotherapy that activates the immune system to fight cancer cells, and clinical trials, such as cancer vaccines. Talk to your doctor about different treatment plans to see what might be best for you.
Maintain Optimal Nutrition and Overall Health
Prioritizing your nutrition and physical activity can help your body tolerate more aggressive treatments and recover from surgery more quickly. Consider working with an oncology nutritionist and physical therapist, who can develop diet and exercise plans that support weight maintenance and muscle strengthening while reducing fatigue and boosting lung capacity.
Monitor and Manage Other Health Concerns
Managing other health conditions can improve your eligibility for surgery and treatment outcomes. Patients who do not suffer from a simultaneous medical concern along with mesothelioma tend to have better survival rates and treatment tolerance.
Consider Clinical Trials
Clinical trials offer access to emerging treatments that may benefit mesothelioma patients who are not responding to other treatments. Researchers continue to develop new immunotherapy protocols and combination treatments that have shown promise for improving mesothelioma outcomes. Ask your doctor about available clinical trials that may help your prognosis and provide valuable information for future treatments.
Understanding Your Personal Mesothelioma Prognosis
Several personal factors affect your mesothelioma prognosis. While national survival statistics provide a general idea, your doctors can give you details that are specific to your case, based on:
- Your specific mesothelioma type, stage, and cell type
- Your age and overall health status
- Your treatment goals and treatment eligibility
- Your individual response to initial treatments
- Access to specialized mesothelioma treatment centers
Through regular visits, mesothelioma specialists can track how your disease is progressing, adjust your treatment plan as needed, and identify new clinical trials that could improve your outlook.
Conclusion: Taking Action to Improve Your Mesothelioma Outlook
If you developed mesothelioma due to negligent exposure to asbestos in the workplace, Mesothelioma law firms, such as Oslund Udo Little, can help you seek compensation that may help cover the cost of medical care and secure your family’s future.
Take Action: If you or a loved one has been diagnosed with mesothelioma, consult with mesothelioma specialists, explore all treatment options, and investigate clinical trial participation. These steps can significantly impact survival outcomes and quality of life.
Sources & References
American Cancer Society. (2024a). How malignant mesothelioma is staged. cancer.org
American Cancer Society. (2024b). Malignant mesothelioma survival rates by stage. cancer.org
American Cancer Society. (2026). Stages of Mesothelioma. cancer.org
American Association for Cancer Research. (2020). First-line immunotherapy approved for advanced mesothelioma. aacr.org
Burt, B. M., Lee, H. S., Lukanich, J. M., Groth, S. S., & Sugarbaker, D. J. (2014). Extrapleural pneumonectomy for malignant pleural mesothelioma: Outcomes, prognostic factors, and surgical accents. The Annals of Thoracic Surgery, 98(5), 1745–1753. annalsthoracicsurgery.org
Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. (2023). Mesothelioma bank information bulletin. cdc.gov
Centonze, G., Alaimo, A., & Melotti, F. (2021). Diagnostic and therapeutic evolution of pleural mesothelioma management. PubMed Central (PMC), PMC8139608. https://pmc.ncbi.nlm.nih.gov/articles/PMC8139608/
Gomez, D. R., Tsao, A. S., & Rice, D. C. (2018). Advanced multimodal care models for malignant mesothelioma. PubMed Central (PMC), PMC9270221. nih.gov
Moffitt Cancer Center. (2024). Clinical guide on malignant mesothelioma survival rates. moffitt.org
National Cancer Institute. (2022). Cancer Staging. cancer.gov
National Cancer Institute. (n.d.). SEER cancer statistics explorer: Incidence and mortality of mesothelioma by sex. cancer.gov
National Cancer Institute. (n.d.). SEER cancer statistics explorer: Survival times of malignant mesothelioma by age metrics. cancer.gov
Nelson, D. B., Rice, D. C., Niu, J., & Tsao, A. S. (2017). Predictors of survival and therapy patterns in malignant pleural mesothelioma. PubMed Central (PMC), PMC5221096. https://pmc.ncbi.nlm.nih.gov/articles/PMC5221096/
Røe, O. D. (2018). Mesothelioma diagnosis and prognosis, are we moving beyond histology and performance status towards circulating biomarkers? Journal of Thoracic Disease, 10(Suppl 17), S1956–S1961. https://pmc.ncbi.nlm.nih.gov/articles/PMC6036040/
Scherpereel, A., Opitz, I., & Astoul, P. (2018). ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. The Lancet Oncology, 19(5), e261–e272. thelancet.com
Taioli E., Wolf A. S., & Flores R. M. (2018). Factors influencing malignant mesothelioma survival: A study of the National Mesothelioma Virtual Bank (NMVB). Journal of Thoracic Oncology, 13(11), 1735-1741. https://pmc.ncbi.nlm.nih.gov/articles/PMC6198263/
Thomas, A., & Hassan, R. (2022). Immunotherapy combinations and frontline trials for malignant pleural mesothelioma. Journal of Thoracic Oncology, 17(8), 1011-1024. sciencedirect.com
Tsao, A. S., Pass, H. I., & Rimner, A. (2021). Multidisciplinary management of pleural mesothelioma: A review of current therapies. Seminars in Thoracic and Cardiovascular Surgery, 33(4), 1145–1156. sciencedirect.com
Vogelzang, N. J., & Rusthoven, J. J. (2015). Thoracic oncology case reviews and historical cisplatin survival indicators. PubMed Central (PMC), PMC4599306. nih.gov
Waterhouse, D., & Garon, E. B. (2021). Targeted therapeutic approaches and cell-type outcomes for advanced thoracic tumors. PubMed Central (PMC), PMC8264689. nih.gov
Wolf, A. S., & Flores, R. M. (2017). Current strategies in surgical resection for mesothelioma. PubMed/MEDLINE, 28972039. nih.gov
Zauderer, M. G., & Rusch, V. W. (2022). Next-generation combinations, tumor treating fields, and biological systemic platforms for pleural malignancies. PubMed/MEDLINE, 36068966. nih.gov